Cost Evaluation of Inhaler Therapies Used in Respiratory Diseases: 1998--2015 Period in Turkey.
Value Health Reg Issues
; 13: 31-38, 2017 Sep.
Article
em En
| MEDLINE
| ID: mdl-29073985
ABSTRACT
BACKGROUND:
With the rise in life expectancy, the burden of chronic diseases, including obstructive pulmonary diseases, has increased throughout the world.OBJECTIVES:
To evaluate the sales trends of inhaler pharmaceuticals.METHODS:
The changes in box sales and sales amounts (in Turkish lira) of inhaler pharmaceuticals during the period 1998 to 2015 were examined and sales were projected for the next 3 years. Pharmaceuticals were classified according to form and pharmacological groups.RESULTS:
The sales of inhaler pharmaceuticals have increased rapidly since 2008. The fastest increase in consumption has occurred in short-acting ß2 agonist preparations and nebulizer pharmaceuticals. Inhaled corticosteroid and long-acting ß2 agonist combination sales have been the highest since 2002, when these products entered the Turkish market.CONCLUSIONS:
The inhaler pharmaceutical market has grown over the years, and this growth will continue in the future. The increased use of short-acting preparations, which should be used as symptom relievers, indicates that treatment management continues to be inadequate.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Nebulizadores e Vaporizadores
/
Broncodilatadores
/
Análise Custo-Benefício
/
Corticosteroides
/
Comércio
/
Doença Pulmonar Obstrutiva Crônica
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article